Imaging of angiogenesis

Cardiac PET and PET/CT Imaging

Volumn , Issue , 2007, Pages 394-411

  Dobrucki, Lawrence W ^a   Sinusas, Albert J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84886122313     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-38295-1_26     Document Type: Chapter

References (49)

1. Fam NP, Verma S, Kutryk M, Stewart DJ. Clinician guide to angiogenesis. Circulation. 2003;108:2613-2618.
2. Sinusas AJ. Imaging of angiogenesis. J Nucl Cardiol. 2004;11:617-633.
3. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242-248.
4. Ito WD, Arras M, Scholz D, Winkler B, Htun P, Schaper W. Angiogenesis but not collateral growth is associated with ischemia after femoral artery occlusion. Am J Physiol. 1997;273(Pt 2):H1255-H1265.
5. Simons M. Angiogenesis: where do we stand now? Circulation. 2005;111:1556-1566.
6. Helisch A, Schaper W. Arteriogenesis: the development and growth of collateral arteries. Microcirculation. 2003;10:83-97.
7. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569-571.
8. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med. 2000;342:626-633.
9. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol. 2002;282:C947-C970.
10. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435-439.
11. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87:1171-1180.
12. Kastrup J, Jorgensen E, Ruck A, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol. 2005;45:982-988.
13. Nunn AD. The biology of technetium based hypoxic tissue localising compounds. In: Machulla H-J, ed. Imaging of Hypoxia. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1999:19-45.
14. Sinusas A. The potential for myocardial imaging with hypoxia markers. Semin Nucl Med. 1999;29:330-338.
15. Martin GV, Caldwell JH, Graham MM, et al. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med. 1992;33:2202-2208.
16. Shelton ME, Dence CS, Hwang DR, Welch MJ, Bergmann SR. Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium. J Nucl Med. 1989;30:351-358.
17. Shi CQ, Sinusas AJ, Dione DP, et al. Technetium-99m-nitroimidazole (BMS181321): a positive imaging agent for detecting myocardial ischemia. J Nucl Med. 1995;36:1078-1086.
18. Rumsey W, Patel B, Kuczynski B, et al. Comparison of two novel technetium agents for imaging ischemic myocardium. Circulation. 1995;92(suppl I): I-181.
19. Rumsey WL, Kuczynski B, Patel B, et al. SPECT imaging of ischemic myocardium using a technetium-99m-nitroimidazole ligand. J Nucl Med. 1995;36:1445-1450.
20. Brack SS, Dinkelborg LM, Neri D. Molecular targeting of angiogenesis for imaging and therapy. Eur J Nucl Med Mol Imaging. 2004;31:1327-1341.
21. Chen X, Sievers E, Hou Y, et al. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia. 2005;7:271-279.
22. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2005;2:e70.
23. Hua J, Dobrucki LW, Sadeghi MM, et al. Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. Circulation. 2005;111:3255-3260.
24. Leong-Poi H, Christiansen J, Heppner P, et al. Assessment of endogenous and therapeutic arteriogenesis by contrast ultrasound molecular imaging of integrin expression. Circulation. 2005;111:3248-3254.
25. Su H, Spinale FG, Dobrucki LW, et al. Evaluation of myocardial matrix metalloproteinase (MMP) mediated post-MI remodeling with a novel radiolabeled MMP inhibitor. J Nucl Cardiol. 2004;11:S20.
26. Su H, Spinale F, Dobrucki L, et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation. 2005;112:3157-3167.
27. Leong-Poi H, Christiansen J, Klibanov AL, Kaul S, Lindner JR. Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha (v)-integrins. Circulation. 2003;107:455-460.
28. Dayton PA, Pearson D, Clark J, et al. Ultrasonic analysis of peptide-and antibody-targeted microbubble contrast agents for molecular imaging of alphavbeta3-expressing cells. Mol Imaging. 2004;3:125-134.
29. Blankenberg FG. Molecular imaging: The latest generation of contrast agents and tissue characterization techniques. J Cell Biochem. 2003;90:443-453.
30. Winter PM, Morawski AM, Caruthers SD, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha (v) beta3-integrin- targeted nanoparticles. Circulation. 2003;108:2270-2274.
31. Winter PM, Caruthers SD, Kassner A, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha (nu) beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 2003;63:5838-5843.
32. Collingridge DR, Carroll VA, Glaser M, et al. The development of [(124) I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res. 2002;62:5912-5919.
33. Li S, Peck-Radosavljevic M, Koller E, et al. Characterization of (123) I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int J Cancer. 2001;91:789-796.
34. Li S, Peck-Radosavljevic M, Kienast O, et al. Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma. Q J Nucl Med Mol Imaging. 2004;48:198-206.
35. Lu E, Wagner WR, Schellenberger U, et al. Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue. Circulation. 2003;108:97-103.
36. Sipkins D, Cheresh D, Kazemi M, Nevin L, Bednarski M, Li K. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998;4:623-626.
37. Harris TD, Kalogeropoulos S, Nguyen T, et al. Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm. 2003;18:627-641.
38. Meoli DF, Sadeghi MM, Krassilnikova S, et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest. 2004;113:1684-1691.
39. Johnson LL, Haubner R, Schofield L, Bouchard M, Schwaiger M. Radiolabeled RGD peptide to image angiogenesis in swine model of hibernating myocardium. Circulation. 2003;108(Suppl. S):405.
40. Lee KH, Jung KH, Song SH, et al. Radiolabeled RGD uptake and alphav integrin expression is enhanced in ischemic murine hindlimbs. J Nucl Med. 2005;46:472-478.
41. Blankenberg FG, Mandl S, Cao YA, et al. Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. J Nucl Med. 2004;45:1373-1380.
42. Lee PC, Kibbe MR, Schuchert MJ, et al. Nitric oxide induces angiogenesis and upregulates alpha (v) beta (3) integrin expression on endothelial cells. Microvasc Res. 2000;60:269-280.
43. Haubner R, Wester H, Reuning U, et al. Radiolabeled alpha (v) beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med. 1999;40:1061-1071.
44. Lindsey ML, Escobar GP, Dobrucki LW, et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis following myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;290:H232-H239.
45. Sadeghi MM, Krassilnikova S, Zhang J, et al. Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo. Circulation. 2004;110:84-90.
46. Meoli D, Bourke B, Hu L, Brown L, Sinusas A. Regional hypoxia correlates with radiolabeled targeted markers of myocardiol angiogenesis in ischemic rat model. J Nucl Med. 2002;43(Suppl. S):8P.
47. Lewis MR. Radiolabeled RGD peptides move beyond cancer: PET imaging of delayedtype hypersensitivity reaction. J Nucl Med. 2005;46:2-4.
48. Dzik-Jurasz A. Angiogenesis imaging in man: a personal view from the pharmaceutical industry. Br J Radiol. 2003;76(special number 1):S81-S82.
49. Isner JM, Losordo DW. Therapeutic angiogenesis for heart failure. Nat Med. 1999;5:491-492.